This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Uroplasty, Inc. Is Being Investigated On Behalf Of Shareholders

SAN DIEGO & MINNETONKA, Minn, July 3, 2013 /PRNewswire/ --  Shareholder rights law firm Robbins Arroyo LLP is investigating whether officers and directors of Uroplasty, Inc. (NASDAQCM: UPI) breached their fiduciary duties to shareholders. Uroplasty, a medical device company, develops, manufactures, and markets products for the treatment of voiding dysfunctions.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36754LOGO)



Robbins Arroyo Investigates Uroplasty's Potential Improper Public Statements Regarding Internal Controls

Robbins Arroyo investigation concerns whether certain of Uroplasty's officers and directors failed to implement adequate internal financial controls.  On June 14, 2013, the company announced a delay in the filing of its annual report on Form 10-K for the year ended March 31, 2013, following the completion of a review of its internal control over financial reporting.  Specifically, the company announced that it had recently discovered problems with internal controls related to expense reimbursement for its employees and that upon conducting a review of the issues, Uroplasty found additional problems related to the recognition of orders and payment of sales commissions at the end of its fiscal quarters.  Further, the company announced that it placed its Chief Financial Officer, Mahedi Jiwani, on administrative leave pending a complete investigation of the company's internal controls.  

On this news, shares of Uroplasty dropped $0.26, or 10.5%, to close at $2.22 on June 14, 2013, and have continued to decline an additional 14%, closing at $2.02 on July 1, 2013.

Robbins Arroyo highlights that Uroplasty shareholders have the option to pursue a shareholder derivative action through which shareholders aim to hold insider wrongdoers accountable for their actions, prevent future misconduct, and bring long-term value back to the company.  Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, DDonahue@robbinsarroyo.com, or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in securities litigation and shareholder rights law.  The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.  For more information, please go to http://www.robbinsarroyo.com.  

Press release link: http://www.robbinsarroyo.com/shareholders-rights-blog/uroplasty-inc/

Attorney Advertising. Past results do not guarantee a similar outcome.  

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs